A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer

A randomised phase III trial of MVAC (methotrexate, vincristine, doxorubicin, cisplatin) vs gemcitabine and cisplatin (GC) (G 1000 mg m(−2) days 1, 8, and 15 plus C 70 mg m(−2) day 2, q 4 wks) indicated GC had similar efficacy and lower toxicity (JCO 2000). Significant haematologic toxicities in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussain, S A, Stocken, D D, Riley, P, Palmer, D H, Peake, D R, Geh, J I, Spooner, D, James, N D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409873/
https://www.ncbi.nlm.nih.gov/pubmed/15292922
http://dx.doi.org/10.1038/sj.bjc.6602112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409873/
https://www.ncbi.nlm.nih.gov/pubmed/15292922
http://dx.doi.org/10.1038/sj.bjc.6602112

Ejemplares similares